Erratum: Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis (Blood (2013) 122:25 (4047-4053) DOI: 10.1182/blood-2013-02-485888);Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

Blood

Volumn 122, Issue 25, 2013, Pages 4047-4053

  Cervantes, Francisco ^a   Vannucchi, Alessandro M ^b   Kiladjian, Jean Jacques ^c   Al Ali, Haifa Kathrin ^d   Sirulnik, Andres ^e   Stalbovskaya, Viktoriya ^e   McQuitty, Mari ^e   Hunter, Deborah S ^f   Levy, Richard S ^f   Passamonti, Francesco ^g   Barbui, Tiziano ^h   Barosi, Giovanni ⁱ   Harrison, Claire N ^j   Knoops, Laurent ^k   Gisslinger, Heinz ^l  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAINT LOUIS HOSPITAL   (France)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Experimental Station   (United States)

^g OSPEDALE DI CIRCOLO   (Italy)

^h OSPEDALI RIUNITI   (Italy)

ⁱ FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^j GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^k CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^l MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RUXOLITINIB;

ABDOMINAL PAIN; ACUTE LEUKEMIA; ADVERSE OUTCOME; ANEMIA; ARTHRALGIA; ARTICLE; ASCITES; ASTHENIA; BACKACHE; BLEEDING; BRAIN HEMORRHAGE; BRONCHITIS; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENDOCARDITIS; EPISTAXIS; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HEART ARREST; HEART FAILURE; HEMATOMA; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INFECTION; INSOMNIA; INTESTINE PERFORATION; KLEBSIELLA INFECTION; LEUKOPENIA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; MYELOFIBROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; OVERALL SURVIVAL; PAIN; PALPATION; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROBABILITY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RETROPERITONEAL HEMORRHAGE; RHINOPHARYNGITIS; SEPSIS; SEPTIC SHOCK; SPLEEN; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

EID: 84891303523     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-11-750505     Document Type: Erratum

References (15)

1. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol. 2008;83(6): 491-497. (Pubitemid 351742799)
2. Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2011;2011: 222-230.
3. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13): 2895-2901.
4. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009; 33(9): 1199-1203.
5. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7): 1723-1735.
6. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15): 3109-3117.
7. Verstovsek S, Mesa RA, Gotlib J, et al. A doubleblind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9): 799-807.
8. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9): 787-798.
9. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5): 937-951.
10. Barosi G, Mesa RA, Thiele J, et al; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2): 437-438. (Pubitemid 351250553)
11. Levine RL, Belisle C, Wadleigh M, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood. 2006; 107(10): 4139-4141. (Pubitemid 43726824)
12. Cervantes F, Kiladjian J, Niederwieser D, et al. Long-term efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for the treatment of myelofibrosis. [abstract] Blood. 2012; 120(21). Abstract 801.
13. Mesa RA, Verstovsek S, Gupta V, et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I. [abstract] Blood. 2012;120(21). Abstract 1733.
14. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012; 119(14): 3219-3225.
15. Kvasnicka HM, Thiele J, Bueso-Ramos C, et al. Long-term intervention effects on bone marrow morphology in myelofibrosis: patients treated with ruxolitinib and best available therapy [abstract]. Haematologica. 2013;98(suppl 1):249. Abstract S591.